CA2960890A1 - Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer - Google Patents
Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer Download PDFInfo
- Publication number
- CA2960890A1 CA2960890A1 CA2960890A CA2960890A CA2960890A1 CA 2960890 A1 CA2960890 A1 CA 2960890A1 CA 2960890 A CA2960890 A CA 2960890A CA 2960890 A CA2960890 A CA 2960890A CA 2960890 A1 CA2960890 A1 CA 2960890A1
- Authority
- CA
- Canada
- Prior art keywords
- vegf
- patient
- patients
- aflibercept
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051091P | 2014-09-16 | 2014-09-16 | |
| US62/051,091 | 2014-09-16 | ||
| US201562099630P | 2015-01-05 | 2015-01-05 | |
| US62/099,630 | 2015-01-05 | ||
| PCT/US2015/049279 WO2016044041A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2960890A1 true CA2960890A1 (en) | 2016-03-24 |
Family
ID=54207741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2960890A Pending CA2960890A1 (en) | 2014-09-16 | 2015-09-10 | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10525104B2 (https=) |
| EP (1) | EP3194974B1 (https=) |
| JP (1) | JP6692358B2 (https=) |
| KR (1) | KR102471057B1 (https=) |
| CN (1) | CN107076749B (https=) |
| AU (1) | AU2015318207B2 (https=) |
| CA (1) | CA2960890A1 (https=) |
| EA (1) | EA036671B1 (https=) |
| IL (1) | IL250905B (https=) |
| MX (1) | MX382673B (https=) |
| WO (1) | WO2016044041A1 (https=) |
| ZA (1) | ZA201701664B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1216765A1 (zh) | 2013-03-14 | 2016-12-02 | 奥特拉西斯公司 | 使用所测分析物改进疾病诊断的方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| RU2018127709A (ru) | 2016-01-22 | 2020-02-25 | Отрэйсис, Инк. | Системы и способы улучшения диагностики заболеваний |
| KR20190131538A (ko) * | 2017-03-31 | 2019-11-26 | 가부시키가이샤 히로츠 바이오 사이언스 | 암 환자의 치료 효과의 예측 및/또는 재발 모니터링 |
| FI3743091T3 (fi) | 2018-01-26 | 2025-01-03 | Univ California | Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| US20210012899A1 (en) * | 2019-07-13 | 2021-01-14 | Otraces, Inc. | Diagnosis for various diseases using tumor microenvironment active proteins |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021076852A1 (en) * | 2019-10-17 | 2021-04-22 | Board Of Regents, The University Of Texas System | Small extracellular vesicle-associated vegf as a predictor for therapeutic responses |
| WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN101283280A (zh) * | 2005-08-18 | 2008-10-08 | Zadec私人有限公司 | 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途 |
| US20110070186A1 (en) * | 2009-08-14 | 2011-03-24 | Allergan, Inc. | Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases |
| AU2011208805A1 (en) * | 2010-01-19 | 2012-06-21 | F. Hoffman-La Roche Ag | Tumor tissue based biomarkers for bevacizumab combination therapies |
| EP2848939A1 (en) * | 2010-07-19 | 2015-03-18 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
-
2015
- 2015-09-10 AU AU2015318207A patent/AU2015318207B2/en active Active
- 2015-09-10 CA CA2960890A patent/CA2960890A1/en active Pending
- 2015-09-10 US US15/509,461 patent/US10525104B2/en active Active
- 2015-09-10 JP JP2017533704A patent/JP6692358B2/ja active Active
- 2015-09-10 WO PCT/US2015/049279 patent/WO2016044041A1/en not_active Ceased
- 2015-09-10 CN CN201580049558.1A patent/CN107076749B/zh active Active
- 2015-09-10 EP EP15771819.8A patent/EP3194974B1/en active Active
- 2015-09-10 EA EA201790549A patent/EA036671B1/ru unknown
- 2015-09-10 MX MX2017003387A patent/MX382673B/es unknown
- 2015-09-10 KR KR1020177007326A patent/KR102471057B1/ko active Active
-
2017
- 2017-03-02 IL IL250905A patent/IL250905B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01664A patent/ZA201701664B/en unknown
-
2019
- 2019-11-21 US US16/690,459 patent/US11439683B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201790549A1 (ru) | 2017-07-31 |
| IL250905B (en) | 2019-12-31 |
| AU2015318207A1 (en) | 2017-04-06 |
| ZA201701664B (en) | 2018-05-30 |
| EP3194974A1 (en) | 2017-07-26 |
| US20200129589A1 (en) | 2020-04-30 |
| KR20170055972A (ko) | 2017-05-22 |
| US11439683B2 (en) | 2022-09-13 |
| KR102471057B1 (ko) | 2022-11-28 |
| US20170281725A1 (en) | 2017-10-05 |
| US10525104B2 (en) | 2020-01-07 |
| JP2017530372A (ja) | 2017-10-12 |
| CN107076749A (zh) | 2017-08-18 |
| MX382673B (es) | 2025-03-13 |
| EP3194974B1 (en) | 2019-10-23 |
| EA036671B1 (ru) | 2020-12-07 |
| CN107076749B (zh) | 2020-12-29 |
| MX2017003387A (es) | 2018-01-30 |
| AU2015318207B2 (en) | 2021-11-04 |
| JP6692358B2 (ja) | 2020-05-13 |
| IL250905A0 (en) | 2017-04-30 |
| WO2016044041A1 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11439683B2 (en) | Anti-angiogenic therapy of metastatic colorectal cancer | |
| AU2011281700B2 (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer | |
| JP6055764B2 (ja) | 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー | |
| KR101523419B1 (ko) | 베바시주맙 병용 치료법을 위한 종양 조직 기본 바이오마커 | |
| Li et al. | Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer | |
| Musaelyan et al. | Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer | |
| EP3463462A1 (en) | Methods of drug therapy selection for breast cancer patients based on her2 and her3 pathway subtyping | |
| JP2019518970A (ja) | 腎臓癌を患う対象の癌治療に対する感受性を予測するための方法およびキット | |
| WO2018124153A1 (ja) | 抗ｖｅｇｆｒ－２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット | |
| WO2016115149A1 (en) | Neuropilin-1 as a serum based biomarker | |
| HK1198063A (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200827 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240826 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240826 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250717 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D21-D152 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: FINAL ACTION WITHOUT REQUEST FOR CONTINUED EXAMINATION Effective date: 20250717 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250821 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260128 |